

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
阿里健康信息技術有限公司
(Incorporated in Bermuda with limited liability)
(Stock code: 00241)

APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

We refer to the announcement (the “**Announcement**”) of Alibaba Health Information Technology Limited (the “**Company**”) dated May 23, 2019 in relation to, among other things, the Ali JK Subscription Agreement entered into between the Company and Ali JK and the Antfin Subscription Agreement entered into between the Company and Antfin on May 23, 2019, respectively (the “**Subscription Agreements**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board wishes to announce that, with the approval of the Independent Board Committee, Somerley Capital Limited, a corporation licensed to carry out Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), has been appointed as the independent financial adviser to advise the Independent Board Committee and the Independent Shareholders in connection with the entry into of the Subscription Agreements. The letter of advice from Somerley Capital Limited in respect of the Subscription Agreements will be included in a circular to be despatched by the Company on or before June 30, 2019.

For and on behalf of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
SHEN Difan
Chief Executive Officer and Executive Director

Hong Kong, June 13, 2019

As at the date of this announcement, the Board comprises eight Directors, of whom (i) two are executive Directors, namely Mr. SHEN Difan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei, (Vanessa).